Anti-TNF medication and tuberculosis
|
|
- Christian Wood
- 6 years ago
- Views:
Transcription
1 Anti-TNF medication and tuberculosis Marleen Bakker Amsterdam
2 Contents Why? Who? How? How? testing + interpretation - 2 treatment
3 Why? Blocking TNF has major effect on immune-mediated inflammatory diseases (IMIDs)! results in increased risk of Mycobacterial infections (Mtb 25x)
4 Who? IMID patients: RA, IBD (Crohn, CU), psoriasis, Bechterew,.. Who ar candidate for use of TNFα inhibitors: Infliximab Remicade Etanercept Enbrel Adalimumab Humira Certolizumab Cimzia Golimumab Simponi
5 Miss D Born in Cabo Verde 2010 uveïtis 2010 M Crohn: immunosuppression, no benefit 2012 Planned to start Adalimumab what do you do?
6 How? 1 Select those pre-antitnf who are at risk for reactivation TB 1A Exclude / diagnose and treat active TB 2 Start treatment latent TB pre start antitnf
7 How - guidelines Diversity of guidelines/statements within Europe TBNET consensus Statement Eur Resp J 2010;36: Dutch Statement Tuberculose en TNF-α blokkerende therapie
8 How testing? - History taking, including results of former TB tests/exposure - Chest x-ray - TST/IGRAs - NB Those tested often are under immunosuppression: radiology and TB tests can be false-negative; negative tests do not exclude TB (infection) - Any positive result is reason to consider latent TB treatment after excluding active TB
9 Guidelines - TBNET Statement: - TST alone not sensitive/specific enough - Too little data in pre-antitnf group to advise IGRA alone - TST in non BCG-vaccinated (10 mm) + IGRA - European: TST IGRA TST and IGRA +/- boosting - Dutch guideline: TST (10 mm; immunosuppressed: 5 mm) and IGRA
10 Miss D Born in Cabo Verde - Adalimumab - Chest x-ray (N); - No latent tb test because of BCG (?) - Advised to seek help in case of complaints - X-ray: test for active TB - history + epidemiology: LTBI - TST and IGRA
11 Miss D - History + epidemiology.. - How? - When start adalimumab?
12 Guidelines - TBNET Statement: 9-12H - 3HR - European: 2RZ(!) 3R 4R 6H 9H 12H 3HR 4HR - Dutch guideline: 4HR - 9H 4R - When start anti-tnf: 4 wks (TBNET) 2 months (dutch) - No preventive treatment for M/XDR TB
13 Miss D Year after start adalimumab starts to cough (?) GP amoxicillin 2 weeks later: fever and night sweats Returns to GP: night sweats and fever and a friend (CV) with lung tb..gp: public health care will contact you So she waits.
14
15 Miss D TB under anti-tnf 1-2% all TB (NTR)..can be hard to diagnose due to lack of clinical symtoms, lack of radiological signs and falsenegative test results. What do you do?
16 Guidelines Stop anti-tnf Start tb treatment immediately; maximal effort to achieve microbiology, molecular tests if possible European = TBNET = dutch Reactivation or (re)infection? Median time after start anti-tnf: 13 months clustered with her friend Kwon et al.: J Clin Rheum 2014;20(2):68-73
17 Miss D At 6 weeks TB treatment: Favorable clinical reaction, normal sensitivity strain Starts to complain about her eyes/crohn, wants to restart anti-tnf What do you advise?
18 Guidelines Preferably after completing TB treatment If no complete treatment: at least a favorable clinical reaction on TB treatment and confirmation of sensitive strain; perferably after intensive phase In life-threatening (neuro-)iris consider restart anti-tnf Clin Infect Dis 2008;47:e83-85
19 Miss D Restart adalimumab at 2 months, very happy even happier when TB treatment stopped at 6 months. Ongoing risk under anti-tnf treatment: - Reinfection - False-negative test results latent/active TB - Reactivation in spite of LTBI-treatment (sensitive/resistant strain)
20 Miss P Healthy law student, 24, dutch Weight loss 8 kg/6 weeks, fever, diarrhea, night sweats GP: appendicits hospital GE: extensive ulceration intestines / biopsy: granulomatous reaction M Crohn
21 Immunosuppression without benefit infliximab (TST negative) Further detoriation condition perforation ileum, extensive TB everywhere abdomen + chest. Weeks at ICU, hardly survived.
22 At 1 year: immense immune reconstitution inflammatory syndrome At 8 years (2014) after correction AP, aesthetic surgery abdomen, lymph node resections and giving birth to healthy daughter.. persistant pus in the liver (Aur+) Partner, 2 sisters and mother: active TB Tegen de Tuberculose 110(1):16-18, 2014
23 Miss P Exceptional case misdiagnosing tb for IMID, but not unique! Arend et al Clin Infect Dis 2007;45: Chest x-ray before start anti-tnf! TB under anti-tnf can go completely out of control testing & treating (L)TB to prevent (very nasty) TB!
24 What we still need. a test for viable Mycobacteria in LTBI optimal testing strategy = optimal selection of patients/optimal PP value for the development of TB under TNF blocking knowledge of optimal LTBI treatment pre anti-tnf (use anti-tnf to shorten LTBI treament??) and, last but not least: a test that differentiates latent from active TB
25 THM Anti-TNF treatment warrants testing and treating (L)TB pre-start. NB Potential risk of any (cellular) immunosuppressive condition! Ongoing risk under TNF-blocking treatment! Work up >> latente TB test: A/LO/X + Mx/IGRA, Diversity in testing and treating within Europe Inform your patient about TB/risks (travelling!). Inform GP! Primary prophylaxis after excluding active TB if exposure under anti-tnf
26 Literature - 1 Statement Tuberculose en TNF-α blokkerende therapie Solovic I, Sester M et al.: The risk of tuberculosis rlated to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Resp J 2010; Diel R et al.: Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and metaanalysis. Eur Resp J 2011;37:88-99 Sester M et al.: Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Resp J 2011;37:
27 Literature - 2 Mack U et al.: LTBI: Latent tuberculosis infection or lasting immune response to M. tuberculosis? A TBNET Consensus Statement. Eur Resp J 20091;33: Smith MY et al.: Tuberculosis screening in prescribors of anti-tumor necrosis factor therapy in the Euroean Union Int J Tuberc Lung Dis 2012;16(9): Cantini et al.: Adalimumab, Etanercept, Infliximab, and the risk of tuberculosis: data from clinical trials, National Registries, and postmarketing surveillance. J Rheum 2014;91:47-55 Cantini et al.: Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α(tnf-α) Targeted Biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. J Rheum Suppl 2014;91:56-64
Communicable Disease Control Manual Chapter 4: Tuberculosis
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationTUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital
TUBERCULOSIS AND THE TNF-α INHIBITORS Lloyd Friedman, M.D. Yale University Milford Hospital Outline TNF-α Anti-TNF-α medications Rates of tuberculosis Lower rates with etanercept Screening for latent tuberculosis
More informationLatent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers
Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Who Should Be Screened for Latent Tuberculosis Infection (LTBI)?... 2 What tests are used to screen for LTBI?... 2 How
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #274: Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy National Quality Strategy Domain: Effective Clinical Care
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationPREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More informationTuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant
Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection
More informationCell-Mediated Immunity and T Lymphocytes
Cell-Mediated Immunity and T Lymphocytes T helper (Th) Cells Peripheral lymhoid tissue thymus Lymphoid stem cell CD8+ CD4+ CD4+ Treg CD8+ CTL + antigen Cytotoxic T lymphocyte CD4+ Th Helper T cell CD4+
More informationJennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health. Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN
Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN Phase Symposium: May 6, 2009 Background & Rationale Maryland
More informationNorthwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationContracts Carla Chee, MHS May 8, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Contracts Carla Chee, MHS May 8, 2012 Carla Chee, MHS has the following disclosures to make: No conflict of interests No relevant
More informationPreventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program
Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program Topics of Discussion TB Overview Epidemiology of TB in Oregon Annual Facility
More informationDIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationCHAPTER 3: DEFINITION OF TERMS
CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
More informationLTBI Treatment and Anti TNF alpha
LTBI Treatment and Anti TNF alpha Therapy Julie Higashi, MD PhD Director, TB Control Section San Francisco Department of Public Health TNF alpha is important for the immune response against TB Macrophages
More informationESCMID Online Lecture Library. by author
Therapies or diseases predisposing to infection Congenital immunodeficiences Acquired conditions Common variable immunedeficiency particular diseases (e.g. HIV, cancer,leukemia, lymphoma, diabetes, cystic
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),
More informationLatent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal
Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal Civil surgeons are required to report tuberculosis (TB) screening outcomes that result in latent TB
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1017-7 Program Prior Authorization/Notification Medication Cimzia (certolizumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationTB testing in children on biologics
TB testing in children on biologics Version: 1 Approval Committee: Date of Approval: Ratification Group (eg Clinical network): Date of Ratification Signature of ratifying Group Chair Author(s) and title
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationClinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
ORIGINAL ARTICLE pissn 1598-9100 eissn 2288-1956 http://dx.doi.org/10.5217/ir.2016.14.2.146 Intest Res 2016;14(2):146-151 Clinical features of active tuberculosis that developed during anti-tumor necrosis
More informationProposed Regs.pdf
Kansas Wesleyan University TB testing Policy In Compliance with Kansas Statue KSA 2009 Supp. 65-129, all Kansas Wesleyan University students who have traveled, resided in for more than three months, or
More informationDiagnosis & Management of Latent TB Infection
Diagnosis & Management of Latent TB Infection Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director Academics, Industry: Research, Diagnosis, Public Health, Academics Adviser: Laboratory Operations,
More informationIn our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between
In our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between the two, we also propose a classification system for
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationRemicade and Friends What You Need to Know Treating the Patient on TNF-alpha Inhibitors and Related Meds
Remicade and Friends What You Need to Know Treating the Patient on TNF-alpha Inhibitors and Related Meds Scott Stienecker MD FACP FSHEA Medical Director for Epidemiology and Infection Prevention Parkview
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier National Quality Strategy
More informationOutline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF
Outline Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic Types of biologic drugs How do they work? How effective are they? Safety/Toxicity concerns with biologics Biologic
More informationo Your healthcare provider should test you for TB before starting CIMZIA.
Medication Guide CIMZIA (CIM-zee-uh) (certolizumab pegol) lyophilized powder or solution for subcutaneous use Read the Medication Guide that comes with CIMZIA before you start using it, and before each
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationLatent tuberculosis (TB) infection (LTBI), a
COMMENTARY Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting Marisa Kardos, BS, and Alexa Boer Kimball, MD,
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationMEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)
MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not
More informationSynoviocytes. Macrophage. B cell C H R O N I C. Neutrophil. Mast cell I N F L A M M A T I O N. Tissue cell. Endothelial cell. Th1/Th17 IL17 IL22
DC IL12, IL23 chemokines, ECM, Co-stimulation IL17, IL22 IFNγ ± Macrophage peptidoglycan lipopolysaccharide heat shock proteins Th1/Th17 IL17 IL22 Cell contact, co-stimulation immune complexes acute phase
More informationTB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014
Sharing the Care: Working Together to Meet the Challenge of TB Presented by: Barbara Cole, RN, PHN, MSN Director, Disease Control County of Riverside Department of Public Health Curry International TB
More informationContact Investigation San Antonio, Texas January 14-15, 2013
Contact Investigation San Antonio, Texas January 14-15, 2013 Assigning Priorities to Contacts Patrick Moonan, PhD, MPH January 14, 2013 Patrick Moonan, PhD, MPH has the following disclosures to make: No
More information2017/2018 Annual Volunteer Tuberculosis Notice
Lewis Center for Educational Research Academy for Academic Excellence Norton Science and Language Academy Business Offices 17500 Mana Road Apple Valley, CA 92307 E-mail: hr@lcer.org 760-946-5414 Fax 760-946-9193
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis. Assessment and Follow-Up of TB Contacts
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Assessment and Follow-Up of TB July, 2018 Page 1 TABLE OF CONTENTS 8.0 ASSESSMENT AND
More informationhas the following disclosures to make:
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash
More informationGuidelines for rheumatology patients on biologic therapy. Rheumatology Department Patient Information Leaflet
Guidelines for rheumatology patients on biologic therapy Rheumatology Department Patient Information Leaflet Introduction In general, people who have biologic therapy for their rheumatic condition (e.g.
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationMonitoring Patients on Biologic Therapies Murlidhar Rajagopalan, MBBS, MD
Monitoring Patients on Biologic Therapies Murlidhar Rajagopalan, MBBS, MD Biologics available for psoriasis 1) tumor necrosis factor alpha (TNF-α) inhibitors, 2) interleukin (IL)-12/23 inhibitors, and
More informationTuberculosis and TNF Inhibitors
Tuberculosis and TNF Inhibitors Sundari Mase MD, MPH Medical Team Lead CDC/DTBE/FSEB January 18, 2011 Objectives Discuss the association between and epidemiology of TNF inhibitors and TB Discuss the challenges
More informationRegulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 10 Last Review Date: June 22, 2017 Humira Description Humira (adalimumab),
More informationSteps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS
Moderate to Severe Rheumatoid Arthritis (RA) 3 Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS INDICATION/USAGE Adult Rheumatoid Arthritis (RA): ORENCIA (abatacept) is a prescription
More informationPrimary Care and TB Control Dr Helen Booth Consultant Thoracic Physician, UCLH Clinical Lead, Integrated TB NCL-Service
Primary Care and TB Control Dr Helen Booth Consultant Thoracic Physician, UCLH Clinical Lead, Integrated TB NCL-Service North Central London TB Service TBService@nhs.net After Action Review Could we have
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 6 Last Review Date: December 8, 2017 Stelara Description Stelara (ustekinumab)
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas August 2-5, 2011 Pediatric TB Jeffrey Starke, MD August 5, 2011 Jeffrey Starke, MD has the following disclosures to make: Is on a data safety monitoring board for Hoffman
More informationDiagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015
Diagnosis and Medical Management of TB Disease Quratulian Annie Kizilbash, MD, MPH March 17, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION Quratulian
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationContemporary Views of the Impact of Biologic Therapy on Infection Risk
Contemporary Views of the Impact of Biologic Therapy on Infection Risk Cezarina Mindru, M.D. Assistant Professor of Medicine Baylor College of Medicine VA Michel E. Debakey, Houston, TX Faculty Disclosures
More informationUnderstanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
More informationTable 9. Policy for Tuberculosis Surveillance and Screening
Policy for Tuberculosis Surveillance and Screening Purpose: to identify active cases of tuberculosis or latent TB among residents and staff of the nursing home in order to prevent transmission in this
More informationTuberculosis: update 2013
Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference
More informationManagement of Pediatric Tuberculosis in New Jersey
Management of Pediatric Tuberculosis in New Jersey Helen Aguila, MD NJMS Global TB Institute December 15, 2011 This presentation is in part adapted from Pediatric Tuberculosis by Ann Loeffler, MD : Francis
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationLATENT TUBERCULOSIS. Robert F. Tyree, MD
LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION
More informationTB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009
TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages
More informationSummary of Key Points WHO Position Paper on BCG Vaccine, February 2018
Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018 1 Introduction This position paper replaces the 2004 WHO position paper on Bacille Calmette-Guérin (BCG) vaccine and the 2007 WHO
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
TB Partial Update Appendix 1 - Scope NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial
More informationTuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
More informationUNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL GOLIMUMAB (SIMPONI)
UNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL GOLIMUMAB (SIMPONI) TREATMENT PROTOCOL: Golimumab is a human monoclonal antibody that specifically binds to human tumor necrosis factor alpha (TNFα) and neutralizes
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationCommunity pharmacy-based tuberculosis skin testing
Community pharmacy-based tuberculosis skin testing Shanna K. O Connor, PharmD ISU KDHS Spring CE Seminar 2018 In support of improving patient care, Idaho State University Kasiska Division of Health Sciences
More informationInterferon gamma release assays and the NICE 2011 guidelines on the diagnosis of latent tuberculosis
CLINICAL AUDIT Clinical Medicine 2013, Vol 13, No 4: 362 6 Interferon gamma release assays and the NICE 2011 guidelines on the diagnosis of latent tuberculosis Helen R Mujakperuo, Richard D Thompson and
More informationContact Investigation Overview
Contact Investigation Overview Jan Dougan, RN May 4, 2017 Essential Skills for the TB Nurse Case Manager Little Rock, AR May 3 4, 2017 Jan Dougan, RN has the following disclosures to make: No conflict
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial update) 1.1 Short title Tuberculosis
More informationA look at medical factors that increase the risk for TB disease
A look at medical factors that increase the risk for TB disease Mark Lobato, MD New England TB Consultant Division of Tuberculosis Elimination CDC Overview The spectrum of M. tuberculosis infection Immune
More informationMEDICATION GUIDE. (tocilizumab)
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Read this Medication Guide before you start ACTEMRA and before each infusion. There may be new information. This Medication Guide does not take the place
More informationMycobacterial diseases developed during anti-tumour necrosis factor-a therapy
ORIGINAL ARTICLE PULMONARY INFECTIONS Mycobacterial diseases developed during anti-tumour necrosis factor-a therapy Jung-Wan Yoo 1, Kyung-Wook Jo 1, Bo-Hyung Kang 1, Mi Young Kim 2, Bin Yoo 3, Chang-Keun
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationUC DavisTB Screening Requirement: How to submit your TB Health Assessment Form
UC DavisTB Screening Requirement: How to submit your TB Health Assessment Form Step 1 If after completing the TB Risk Screening you are found to be at high risk, you must complete the Tuberculosis (TB)
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationSanta Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014
Guidelines to Revisions to the School Mandate and Requirements 1) What are the tuberculosis (TB) screening requirements for school entrance in Santa Clara County? Students must undergo a TB risk assessment
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationTumor Necrosis Factor-alpha 저해제가결핵발생에미치는영향
한국임상약학회지제 28 권제 4 호 Korean J Clin Pharm, Vol. 28, No. 4, 2018 Original Article Korean Journal of Clinical Pharmacy Official Journal of Korean College of Clinical Pharmacy pissn 1226-6051 eissn 2508-786X
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationTB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
More information